We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+18.5%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
+$31.2M
Cap. Flow
+$169M
Cap. Flow %
8.75%
Top 10 Hldgs %
45.68%
Holding
151
New
31
Increased
40
Reduced
42
Closed
31

Top Buys

Rank Stock Value
1
ENSG icon
The Ensign Group
ENSG
+$104M
2
EHC icon
Encompass Health
EHC
+$86.2M
3
CTRE icon
CareTrust REIT
CTRE
+$42.1M
4
UNH icon
UnitedHealth
UNH
+$19M
5
INSM icon
Insmed
INSM
+$18.1M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$68.9M
2
NTRA icon
Natera
NTRA
+$44.5M
3
DOC icon
Healthpeak Properties
DOC
+$32.5M
4
AVTR icon
Avantor
AVTR
+$23.3M
5
QGEN icon
Qiagen
QGEN
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.53%
2 Real Estate 5.59%
3 Miscellaneous 4.84%
4 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMS icon
51
NewAmsterdam Pharma
NAMS
$3.04B
$9.34M 0.48%
275,471
-10,293
-4% -$339K
RVTY icon
52
Revvity
RVTY
$14.5B
$9.3M 0.48%
83,624
-1,230
-1% -$118K
PALI icon
53
Palisade Bio
PALI
$364M
$8.74M 0.45%
4,182,785
-804,714
-16% -$1.58M
ARDX icon
54
Ardelyx
ARDX
$976M
$8.56M 0.44%
1,678,345
-551,101
-25% -$3.36M
MLYS icon
55
Mineralys Therapeutics
MLYS
$2.49B
$8.36M 0.43%
+309,689
New +$8.5M
RLAY icon
56
Relay Therapeutics
RLAY
$4.17B
$8.13M 0.42%
434,314
+163,609
+60% +$2.38M
NVO
57
Novo Nordisk
NVO
$206B
$8.11M 0.42%
+169,227
New +$7.27M
BHVN icon
58
Biohaven
BHVN
$2.37B
$7.68M 0.4%
+515,804
New +$5.55M
PTGX icon
59
Protagonist Therapeutics
PTGX
$9.43B
$7.17M 0.37%
+58,504
New +$6.11M
ELVN icon
60
Enliven Therapeutics
ELVN
$4.35B
$6.93M 0.36%
+136,631
New +$5.8M
REPL icon
61
Replimune Group
REPL
$1.42B
$6.53M 0.34%
590,252
+255,391
+76% +$1.56M
LBRX
62
LB Pharmaceuticals
LBRX
$1.59B
$5.96M 0.31%
183,663
+83,465
+83% +$2.45M
BEAM icon
63
Beam Therapeutics
BEAM
$3.06B
$5.71M 0.3%
+166,289
New +$5.02M
NHI icon
64
National Health Investors
NHI
$3.48B
$5.39M 0.28%
+70,673
New +$5.41M
RARE icon
65
Ultragenyx Pharmaceutical
RARE
$1.51B
$5.15M 0.27%
154,130
+91,555
+146% +$2.27M
PACS icon
66
PACS Group
PACS
$6.73B
$5.01M 0.26%
+117,441
New +$4.22M
XBI icon
67
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.4B
$4.91M 0.25%
31,000
+1,000
+3% +$135K
EQ icon
68
Equillium
EQ
$140M
$4.87M 0.25%
1,520,824
+21,831
+1% +$52.3K
ANAB icon
69
AnaptysBio
ANAB
$1.68B
$4.72M 0.25%
69,983
+42,894
+158% +$2.6M
NHC icon
70
National Healthcare
NHC
$3.42B
$4.67M 0.24%
+22,116
New +$4.06M
EYPT icon
71
EyePoint Inc
EYPT
$395M
$4.26M 0.22%
+297,735
New +$3.98M
SNDA icon
72
Sonida Senior Living
SNDA
$1.81B
$4.19M 0.22%
102,624
+74,187
+261% +$2.66M
GKOS icon
73
Glaukos
GKOS
$10.5B
$4.1M 0.21%
29,343
-30,871
-51% -$3.91M
AGL icon
74
Agilon Health
AGL
$1.49B
$4.05M 0.21%
37,792
-138,796
-79% -$9.09M
ARQT icon
75
Arcutis Biotherapeutics
ARQT
$3B
$3.55M 0.18%
135,355
-441,225
-77% -$10.3M
1 2
3
4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Eversept Partners held 151 positions worth $1.93B, up 1.6% from $1.9B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Eversept Partners deployed $169M of net new capital in Q2 2026, opening 31 new positions and adding to 40 existing holdings. Its largest new stake was CareTrust REIT: 1,072,015 shares worth $43.3M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 74% a quarter earlier, followed by Real Estate and Miscellaneous.

On the sell side, the largest reduction was GSK, an estimated $68.9M trimmed.

  • Eversept Partners's largest Q2 2026 buy was CareTrust REIT: 1,072,015 shares worth $43.3M.
  • Eversept Partners added most to The Ensign Group in Q2 2026, an estimated $104M increase.
  • Eversept Partners's biggest Q2 2026 reduction was GSK, cutting an estimated $68.9M.
  • Eversept Partners fully exited Healthpeak Properties in Q2 2026, selling an estimated $32.5M.
  • Eversept Partners's ten largest holdings make up 46% of its $1.93B portfolio in Q2 2026.
  • Eversept Partners opened 31 new positions and closed 31 in Q2 2026.
  • Eversept Partners's portfolio value rose 1.6% quarter-over-quarter to $1.93B.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.